Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab in CD20+ B-cell malignancies
NCT02290951Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of odronextamab in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Adverse Events at 24 months, Dose Limiting Toxicities at 28 days and 1 more. Started Jan 2015; status: completed.
02
Drugs
odronextamab
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02290951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02290951.